ALFRED D. STEINBERG, M.D.; H. BENFER KALTREIDER, M.D.; PARKER J. STAPLES, M.D.; EDWARD J. GOETZL, M.D.; NORMAN TALAL, M.D.; JOHN L. DECKER, M.D., F.A.C.P.
Thirteen women with lupus nephritis were hospitalized for a 10-week double-blind therapeutic trial comparing oral cyclophosphamide with placebo. Concurrent corticosteroid therapy, up to 30 mg/day of prednisone, was permitted. Patients receiving cyclophosphamide had greater improvement than did placebo-treated patients in five indexes: anti-DNA antibodies, serum complement, urine sediment, proteinuria, and extrarenal disease. There was no difference in creatinine clearance. There was a strong positive correlation between cyclophosphamide dosage and number of indexes improved. Toxic side effects of cyclophosphamide were noted.
Learn more about subscription options.
Register Now for a free account.
STEINBERG AD, KALTREIDER HB, STAPLES PJ, GOETZL EJ, TALAL N, DECKER JL. Cyclophosphamide in Lupus Nephritis: A Controlled Trial. Ann Intern Med. 1971;75:165-171. doi: 10.7326/0003-4819-75-2-165
Download citation file:
Published: Ann Intern Med. 1971;75(2):165-171.
Autoimmune Kidney Disease, Lupus Erythematosus, Nephrology, Rheumatology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only